Xenon Pharmaceuticals (XENE) Income from Non-Controlling Interests (2022 - 2026)
Xenon Pharmaceuticals' (XENE) quarterly Income from Non-Controlling Interests came in at -$1.5 million in Q1 2026, down 299.23% year-on-year from $776000.0 in Q1 2025, and down 524.73% on a QoQ basis from $364000.0 in Q3 2025.
Xenon Pharmaceuticals (XENE) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 5 years of Income from Non-Controlling Interests data on file, last reported at -$1.5 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | - |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | - |
| 10 | Xenon Pharmaceuticals | 5.77 Bn | 5.77 Bn | - | -1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.55 Mn |
| Sep 30, 2025 | 364,000.00 |
| Jun 30, 2025 | 949,000.00 |
| Mar 31, 2025 | 776,000.00 |
| Sep 30, 2024 | 3.55 Mn |
| Jun 30, 2024 | -443,000.00 |
| Mar 31, 2024 | -1.69 Mn |
| Sep 30, 2023 | 346,000.00 |
| Jun 30, 2023 | -1.48 Mn |
| Mar 31, 2023 | 1.18 Mn |
| Sep 30, 2022 | -1.97 Mn |